This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Respiratory distress syndrome of newborn신생아의 호흡곤란증후군

Contents and key points
ItemDetails
A. Classification codesICD-10: P22.0 (Respiratory distress syndrome of newborn) | Special Copayment Reduction: V142 (severe intractable disease, 5 years)
B. SynonymsHyaline membrane disease (HMD), neonatal RDS, neonatal respiratory distress syndrome, surfactant deficiency lung disease
C. Adult onsetAdult onset: none — a neonate-specific disease that presents immediately after birth (mainly within a few hours). It is caused by pulmonary surfactant deficiency in preterm infants, and no adult-onset cases exist.
1. History1950s: concept of hyaline membrane disease established → 1959: Avery and Mead identify surfactant deficiency → 1970s–80s: introduction of CPAP and mechanical ventilation → 1990: FDA approval of surfactant replacement therapy → mortality greatly reduced by antenatal steroids and postnatal surfactant.
2. CausesPulmonary surfactant (mainly phosphatidylcholine) deficiency; preterm birth (especially <34 weeks), diabetic mother, cesarean section (before labor), multiple gestation, male sex, perinatal asphyxia.
3. GeneticsVariants in SFTPB (SP-B), SFTPC (SP-C), ABCA3, NKX2-1 (TTF-1) genes; surfactant metabolism disorders; familial RDS rarely reported.
4. General epidemiology<28 weeks: about 60–80%; 32–34 weeks: about 15–30%; term infants: <1%. About 2,000–3,000 cases per year in Korea (absolute number trending downward due to low birth rate).
5. PathophysiologyAlveolar surfactant deficiency → increased surface tension → alveolar collapse → hypoxemia and hypercapnia → capillary injury and protein exudation → hyaline membrane formation → vicious cycle.
6. SymptomsOnset within a few hours after birth; tachypnea (RR>60), substernal and intercostal retractions, grunting, nasal flaring, cyanosis.
7. SignsChest radiograph: diffuse ground-glass opacity, air bronchograms; hypoxemia (decreased PaO₂, increased FiO₂ requirement); respiratory acidosis.
8. ScreeningPrenatal: amniotic fluid L/S ratio, presence of PG; evaluation of indications for antenatal steroid administration; SpO₂ monitoring of at-risk newborns immediately after birth.
9. DiagnosisClinical symptoms + chest radiograph; arterial blood gas analysis; exclusion of other causes of respiratory distress (infection, pneumothorax, CHD, etc.).
10. TreatmentIntratracheal surfactant administration (INSURE, LISA/MIST techniques); CPAP; invasive mechanical ventilation (only when needed); antenatal steroids (betamethasone/dexamethasone); supplemental oxygen.
11. PrognosisMortality greatly reduced with modern treatment (<10%); major complications: BPD, IVH, ROP, NEC; long-term neurodevelopmental follow-up needed for extremely preterm infants.
12. PreventionAntenatal corticosteroids (when at risk of preterm birth before 34 weeks); prevention of preterm birth (magnesium sulfate, tocolytics); determination of optimal timing of delivery; glycemic control in diabetic mothers.
13. ReferencesSweet DG et al. European Consensus Guidelines on RDS, 2023 and 9 other references

1. History

The history of neonatal respiratory distress syndrome (RDS) parallels the development of intensive care for preterm infants. It was recognized as a leading cause of death in preterm infants until the early 20th century, but specific etiologic understanding began in earnest after the 1950s. In 1953, Virginia Apgar devised the Apgar score for evaluating the condition of newborns, making standardized assessment of the respiratory and circulatory status of newborns immediately after birth possible.

In 1959, Mary Ellen Avery and Jere Mead experimentally demonstrated surfactant deficiency in the lung tissue of preterm infants who died of RDS. This discovery was a decisive turning point in establishing that the etiology of hyaline membrane disease (HMD) is surfactant deficiency due to failure of lung maturation, and it fundamentally changed the paradigm of treatment strategy. Around the same time, the death of Patrick Kennedy, son of President John F. Kennedy, from preterm RDS in 1963 greatly promoted public interest and investment in neonatal intensive care research in the United States.

In 1971, Gregory et al. first introduced continuous positive airway pressure (CPAP) for RDS treatment and reported that it could prevent alveolar collapse and improve oxygenation. CPAP subsequently became established as the standard noninvasive respiratory support therapy and contributed to dramatically reducing dependence on mechanical ventilation.

In 1972, Liggins and Howie published the results of a randomized controlled trial showing that antenatal corticosteroids (betamethasone) greatly reduced the incidence of neonatal RDS in pregnant women at risk of preterm birth. This study is regarded as one of the most influential in the history of neonatology, and antenatal steroids were subsequently established as standard care when preterm birth before 34 weeks is at risk.

In the 1980s, clinical research on surfactant replacement therapy began in earnest. In 1980, Fujiwara et al. published the first clinical results of successfully treating RDS in preterm infants using natural bovine surfactant, and the US FDA approved an artificial surfactant (colfosceril palmitate, Exosurf) in 1990 and a natural surfactant (beractant, Survanta) in 1991. With the introduction of surfactant replacement therapy, RDS-related mortality decreased by about 50% from 1975 to 2000.

After the 2000s, the INSURE (INtubation-SURfactant-Extubation) technique and minimally invasive surfactant administration methods (LISA: Less Invasive Surfactant Administration; MIST: Minimally Invasive Surfactant Therapy) were developed. These techniques aim to administer surfactant effectively while reducing ventilator-induced lung injury (VILI), and are currently the preferred methods in European guidelines. The European RDS consensus guidelines updated in 2023 prefer LISA/MIST under CPAP and recommend minimizing initial invasive mechanical ventilation.


2. Causes

The fundamental cause of neonatal RDS is quantitative deficiency or functional failure of pulmonary surfactant. Surfactant is a complex of phospholipids and proteins synthesized and secreted by alveolar epithelial cells (type II pneumocytes), and it lowers surface tension at the alveolar-air interface to prevent alveolar collapse at end-expiration. The main component of surfactant is phosphatidylcholine (especially dipalmitoyl-PC, DPPC), and surfactant proteins (SP-A, SP-B, SP-C, SP-D) play an essential role in surface-active function.

Preterm birth (main risk factor)

Preterm birth is the most important causative factor of RDS. Differentiation of type II pneumocytes and surfactant synthesis and secretion begin at about 24 weeks of gestation and mature at 34–36 weeks, so with birth earlier than this, surfactant is functionally insufficient. The shorter the gestational age, the higher the incidence and severity of RDS, and the incidence reaches 60–80% in extremely preterm infants born before 28 weeks. Male infants have delayed lung maturation compared with females, so the risk of RDS is higher at the same gestational age (male predominance ratio about 1.5–2 times).

Diabetic mother

In diabetic pregnant women (including gestational diabetes), fetal hyperinsulinemia suppresses the cortisol-driven signal that promotes surfactant synthesis, delaying lung maturation. Therefore, infants of diabetic mothers have a higher risk of RDS than normal newborns of the same gestational age.

Cesarean section and mode of delivery

Cesarean delivery performed without labor increases the risk of RDS. Catecholamines secreted by the mother during labor promote absorption of fetal alveolar fluid and stimulate surfactant release, and surgical delivery performed without labor lacks this signal. This is also related to the increased risk of transient tachypnea of newborn (TTN) with term cesarean section.

Perinatal asphyxia

Hypoxic-ischemic injury around delivery can cause damage to type II pneumocytes and inactivation of surfactant, inducing or worsening RDS.

Other risk factors

Includes multiple gestation (especially the second twin), gene variants related to lung maturation (SFTPB, SFTPC, ABCA3), male sex, white race (some reports of higher RDS risk than in Asians), and family history.


3. Genetics

Most RDS is a developmental problem occurring in preterm infants and has little direct association with single-gene variants. However, special forms of surfactant dysfunction are explained by gene variants. Such hereditary surfactant dysfunction is rare but can cause intractable RDS or persistent lung disease occurring in term or near-term infants.

SFTPB gene (surfactant protein B)

SP-B (surfactant protein B) is the most important hydrophobic protein for the surface-active function of surfactant and is encoded by the SFTPB gene (2p11.2). Loss-of-function mutations (frameshift, nonsense) in the SFTPB gene cause complete SP-B deficiency, leading to fatal respiratory failure immediately after birth. It is inherited in an autosomal recessive manner, and the most common variant is c.397delC (121ins2). SP-B deficiency responds poorly to surfactant replacement therapy and mechanical ventilation, and lung transplantation is known to be the only curative approach.

SFTPC gene (surfactant protein C)

Mutations in the SFTPC gene (8p21.3) show autosomal dominant inheritance and cause intracellular accumulation of abnormal SP-C protein and damage to type II pneumocytes. A representative variant is p.I73T, which presents at various times from the neonatal period through childhood and can progress to chronic interstitial lung disease.

ABCA3 gene

The ABCA3 (ATP-binding cassette transporter A3) gene is essential for DPPC transport in lamellar bodies of surfactant. Loss-of-function mutations in ABCA3 cause abnormal surfactant composition, leading to fatal respiratory failure in the neonatal period or interstitial lung disease in childhood. It is inherited in an autosomal recessive manner.

NKX2-1 gene (TTF-1)

NKX2-1 (thyroid transcription factor-1, TTF-1) is a transcription factor involved in the development of the lung, thyroid, and brain, and regulates transcription of the SFTPB, SFTPC, and ABCA3 genes. NKX2-1 haploinsufficiency or loss-of-function mutations cause brain-lung-thyroid syndrome, characterized by neonatal respiratory failure, thyroid dysfunction, and cerebellar ataxia.

Genetic background in common preterm RDS

There are studies indicating that, even in common preterm RDS, polymorphisms of surfactant protein genes influence the risk and severity of RDS. There are reports that SP-A gene (SFTPA1, SFTPA2) polymorphisms and the SP-B gene c.1580C>T polymorphism are associated with RDS risk, but the evidence for clinical use is not yet sufficient.


4. General epidemiology

The incidence of neonatal RDS varies dramatically with gestational age. Worldwide, RDS is a leading cause of morbidity and mortality in preterm infants, occurring almost universally in extremely preterm infants in particular.

Incidence by gestational age

Incidence is reported at about 60–80% in extremely preterm infants born before 28 weeks, about 50–60% at 28–30 weeks, about 30–40% at 30–32 weeks, and about 15–25% at 32–34 weeks. It is about 5–10% in late preterm infants at 34–36 weeks and less than 1% in term infants (37 weeks or more). With increasing use of antenatal steroids, incidence has been gradually decreasing, and RDS-related mortality has also continued to decline with advances in surfactant therapy and noninvasive respiratory support.

Sex differences

Male infants have delayed lung maturation compared with females, and the incidence of RDS at the same gestational age is about 1.5–2 times higher. This is explained by the fact that estrogen promotes lung maturation in females, whereas androgens suppress surfactant synthesis.

Epidemiology in Korea

In Korea, according to Health Insurance Review & Assessment Service (HIRA) statistics and neonatal intensive care unit data, the annual number of RDS patients is estimated at 2,000–3,000. The absolute number of cases is trending downward due to the low birth rate, but because the proportion of preterm infants among live births is maintained, the incidence of RDS among preterm infants is similar to that in developed countries. According to the Korean Society of Neonatology guidelines, survival of preterm infants born before 28 weeks has improved greatly since the 2000s, and the number of centers showing survival of 50% or more even at 23–24 weeks has increased.

Mortality trends

Before the introduction of surfactant therapy and antenatal steroids, neonatal mortality due to RDS was very high, but it has decreased markedly since the 1990s. In the modern neonatal intensive care setting, mortality due to RDS itself is extremely low in term infants, and even in preterm infants comorbid conditions (intracranial hemorrhage, necrotizing enterocolitis, sepsis, etc.) often determine the prognosis.


5. Pathophysiology

The pathophysiology of RDS is explained as a vicious cycle of worsening that starts with surfactant deficiency. In normal alveoli, surfactant reduces surface tension according to Laplace's law, preventing air from moving from small alveoli to large alveoli and causing their collapse.

Initial mechanism: alveolar collapse and hypoxemia

In preterm lungs deficient in surfactant, alveolar surface tension increases at end-expiration and the alveoli collapse (atelectasis). Alveolar collapse increases ventilation-perfusion mismatch (V/Q mismatch) and intrapulmonary right-to-left shunt, causing hypoxemia. As the newborn's compensatory mechanism for hypoxemia, inspiratory effort increases (overload of respiratory muscles) and the inspiratory pressure needed to open the alveoli rises. However, in the surfactant-deficient state lung compliance is decreased, so ventilation is limited even at the same pressure.

Lung injury and hyaline membrane formation

Hypoxemia and hypercapnia cause pulmonary vasoconstriction, reducing pulmonary blood flow and causing alveolar-capillary injury. Serum proteins (fibrin, immunoglobulins, etc.) exude from the damaged vessels into the alveoli, and these combine with necrotic debris of alveolar epithelial cells and bronchiolar epithelium to form hyaline membranes. Hyaline membranes further impair alveolar-capillary oxygen diffusion and further inhibit surfactant function, forming a vicious cycle. These hyaline membranes are seen as eosinophilic membranes in H&E-stained pathology specimens, which is the origin of the name 'hyaline membrane disease'.

Extrapulmonary mechanism: patent ductus arteriosus and extrapulmonary shunt

Increased pulmonary vascular resistance increases right-to-left shunting through the ductus arteriosus, which worsens systemic hypoxemia. In addition, decreased pulmonary blood flow due to pulmonary vasoconstriction further limits the substrate and oxygen supply needed for alveolar surfactant synthesis, deepening surfactant deficiency.

Natural course

Untreated severe RDS reaches its worst state at 24–72 hours after birth, after which gradual recovery occurs in the natural course through proliferation of type II pneumocytes and increased surfactant production. However, in severe RDS, progression to chronic lung disease (bronchopulmonary dysplasia, BPD) due to oxygen toxicity, barotrauma, and volutrauma during this period is common.


6. Symptoms

The clinical symptoms of RDS are characterized by onset within a few hours after birth, and respiratory distress newly appearing after 6 hours of age strongly suggests causes other than RDS (pneumonia, aspiration syndrome, heart disease, etc.).

Tachypnea

Tachypnea with a respiratory rate of 60 breaths per minute or more is the most basic initial symptom. The respiratory rate increases as a compensatory response to hypoxemia and hypercapnia, and in severe cases may exceed 80–100 breaths per minute.

Substernal and intercostal retractions

Because of decreased lung compliance, high negative pressure is generated during inspiration, and soft tissue retractions are observed in the substernal, intercostal, and supraclavicular areas as a result. The extent and depth of retractions reflect the severity of RDS.

Grunting

A compensatory mechanism of the newborn that partially closes the vocal cords during expiration to create natural PEEP (positive end-expiratory pressure). It is a reflex behavior to prevent alveolar collapse at end-expiration and is a characteristic symptom of RDS. Grunting audible without a stethoscope suggests severe respiratory distress.

Nasal flaring

An expression of use of accessory respiratory muscles to widen the nostrils to reduce inspiratory resistance. When it occurs together with chest retractions, tachypnea, and grunting, it indicates moderate or greater respiratory failure.

Cyanosis

Peripheral cyanosis (acrocyanosis) is relatively common in newborns, but in RDS central cyanosis (bluish discoloration of the oral mucosa, tongue, and trunk) appears. Central cyanosis indicates decreased PaO₂ or decreased oxygen saturation (SpO₂), and SpO₂ below 90% on room air is an indicator for immediate supplemental oxygen or starting respiratory support.

Use of accessory respiratory muscles and abnormal breathing pattern

Thoracoabdominal dyssynchrony (seesaw breathing) occurs with upper airway obstruction or severely decreased lung compliance, and is a paradoxical breathing pattern in which the abdomen expands during inspiration while the chest retracts. This suggests severe respiratory failure.


7. Signs

In the diagnosis of RDS, chest radiograph findings and blood gas analysis provide the key objective signs.

Chest radiograph findings

The typical chest radiograph findings of RDS are diffuse fine reticulogranular/ground-glass opacity and air bronchogram. Fine ground-glass opacity is a finding in which the whole lung looks hazy due to countless microscopic alveolar collapses, appearing homogeneously and bilaterally. Air bronchograms are a finding in which air-filled bronchi are seen in a branching pattern against an opaque background when the alveoli are collapsed. In severe RDS, the borders of the heart and diaphragm become indistinct, and in the most severe cases the lungs become almost completely opaque, appearing as a 'white-out'. Chest radiograph findings are important for assessing the progression of RDS and the response to treatment, and improvement is seen within a few hours after surfactant administration.

Arterial blood gas analysis

Hypoxemia (decreased PaO₂, decreased FiO₂/PaO₂ ratio) is seen, with hypocapnia initially (due to hyperventilation) and hypercapnia in severe cases (respiratory muscle fatigue and decreased alveolar ventilation). Respiratory acidosis (decreased pH, increased PaCO₂) is characteristic of severe RDS, and metabolic acidosis due to tissue hypoxia may accompany.

Lung mechanics indices

Decreased lung compliance (normal: 1–2 mL/cmH₂O/kg; RDS: 0.3–0.5 mL/cmH₂O/kg), increased work of breathing, and decreased functional residual capacity (FRC) are observed. Recently, lung ultrasound has been used in the NICU for diagnosing RDS and determining the timing of surfactant administration, with B-line coalescence, lung consolidation, and an irregular pleural line as characteristic findings.

Laboratory findings

Preterm infants tend to have hypoglycemia, and abnormalities of serum electrolytes (sodium, potassium, calcium) may accompany. Perform a complete blood count (CBC), CRP, and blood culture early to exclude infection. In RDS, CRP is initially normal, and if elevated, accompanying sepsis should be suspected.


8. Screening

Screening for RDS is broadly divided into prenatal assessment of lung maturity and active surveillance of high-risk newborns after birth.

Prenatal assessment of lung maturity

Amniotic fluid lecithin/sphingomyelin ratio (L/S ratio) is a classic indicator of lung maturity; L/S ≥2.0 suggests lung maturity, and the risk of RDS increases at <2.0. Phosphatidylglycerol (PG) is one of the components of surfactant, and PG positivity strongly suggests lung maturity. These tests can be referred to in determining the timing of delivery in mothers at risk of preterm birth, but with the spread of antenatal steroids and advances in surfactant therapy, their clinical use has now decreased.

Antenatal steroid administration

For all pregnant women at risk of preterm birth before 34 weeks, administration of betamethasone 12 mg intramuscularly twice (24 hours apart) or dexamethasone 6 mg four times (12 hours apart) is recommended. Antenatal steroids reduce the incidence of RDS by about 40–60% and also significantly reduce intracranial hemorrhage, necrotizing enterocolitis, and neonatal mortality.

Surveillance of high-risk newborns after birth

Preterm infants born before 34 weeks, infants of diabetic mothers, and infants born by cesarean section without labor need intensive surveillance from immediately after birth. Continuous SpO₂ monitoring with a pulse oximeter is basic, and if the SpO₂ difference between the right-sided (pre-ductal: right wrist or finger) and left-sided (post-ductal: toe) arteries is >3–5%, a right-to-left shunt through a patent ductus arteriosus is suggested. When signs of respiratory distress appear, chest radiograph and arterial blood gas analysis are performed immediately.


9. Diagnosis

The diagnosis of RDS is based on a comprehensive evaluation of clinical symptoms, chest radiograph findings, and arterial blood gas analysis, and differentiation from neonatal respiratory distress of other causes is important.

Clinical diagnosis

RDS is diagnosed clinically when tachypnea, chest retractions, grunting, and cyanosis appear immediately after birth in a preterm infant of less than 34 weeks' gestation and typical ground-glass opacity and air bronchograms are seen on chest radiograph. Decreased PaO₂/FiO₂ ratio and respiratory acidosis on arterial blood gas analysis support the diagnosis. Severity is assessed by the required FiO₂ level (FiO₂ >0.3–0.4 is moderate or greater), the method of respiratory support (CPAP, high-flow oxygen, mechanical ventilation), and blood gas findings.

Differential diagnosis

The main diseases to be differentiated from RDS include neonatal sepsis/pneumonia (onset within the first 6 hours of life, chest radiograph findings may be similar), transient tachypnea of the newborn (TTN: occurs mainly in term or late preterm infants, resolves spontaneously), meconium aspiration syndrome (MAS: term or post-term infants, patchy opacities on chest radiograph), pneumonia (group B streptococcal pneumonia has radiographic findings similar to RDS), congenital diaphragmatic hernia (CDH: abnormal breath sounds on auscultation, gastrointestinal tract located in the thoracic cavity), congenital heart disease (CHD: heart murmur, cardiomegaly), and air leak syndrome (pneumothorax: unilateral decreased breath sounds, pneumothorax on chest radiograph).

Lung ultrasound

Recently, lung ultrasound (LUS) has been used in the neonatal intensive care unit for diagnosing RDS and assessing its severity. On LUS, B-line coalescence (lung interstitial syndrome pattern), lung consolidation, and pleural line irregularity are seen in RDS. LUS can be repeated without radiation exposure, making it useful for assessing response after surfactant administration.


10. Treatment

RDS treatment consists of three pillars: surfactant replacement therapy, respiratory support, and antenatal prevention. Modern treatment strategy has evolved toward giving surfactant early while minimizing mechanical ventilation and maintaining noninvasive respiratory support as much as possible.

Surfactant replacement therapy

Natural animal-derived surfactant (beractant [Survanta], poractant alfa [Curosurf], calfactant [Infasurf]) or synthetic surfactant (lucinactant [Surfaxin], CHF5633) is administered intratracheally. Administration methods include ① INSURE (INtubation-SURfactant-Extubation): surfactant administration after endotracheal intubation, followed by immediate extubation and conversion to CPAP; ② LISA (Less Invasive Surfactant Administration)/MIST (Minimally Invasive Surfactant Therapy): a method of administering surfactant into the trachea through a thin catheter (thin gastric tube or vascular catheter) while maintaining spontaneous breathing, which avoids endotracheal intubation and mechanical ventilation. The 2023 European RDS guidelines recommend LISA/MIST under CPAP as the preferred method. Early rescue surfactant: early administration when FiO₂ >0.30 or CPAP is required is preferred over prophylactic administration, and repeat dosing is possible up to a maximum of 3 doses at 12-hour intervals.

Noninvasive respiratory support: CPAP

Nasal CPAP from the early period after birth is the key to RDS prevention and treatment. CPAP prevents alveolar collapse, maintains FRC, and improves ventilation-perfusion mismatch. Initial CPAP pressure generally starts at 5–8 cmH₂O and is adjusted according to clinical response. High-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) are also used.

Invasive mechanical ventilation

When CPAP fails (failure to maintain SpO₂ despite FiO₂ >0.30–0.40, PaCO₂ >60 mmHg with pH <7.25, severe apnea, etc.), endotracheal intubation and mechanical ventilation are needed. Lung-protective ventilation: VILI is minimized by a strategy of low tidal volume (4–6 mL/kg), appropriate PEEP (4–6 cmH₂O), and permissive hypercapnia (PaCO₂ 45–55 mmHg allowed). High-frequency oscillatory ventilation (HFO) is used as an alternative in severe RDS unresponsive to conventional mechanical ventilation.

Antenatal corticosteroids

Betamethasone or dexamethasone is given to pregnant women expected to deliver before 34 weeks. Maximum effect occurs when given 48 hours to 7 days before delivery, but administration is recommended even when less than 48 hours remain. Antenatal steroids have the effects of promoting lung maturation (increased surfactant synthesis), reducing the incidence of RDS, reducing the risk of IVH, and reducing the risk of NEC.

Supportive care

Includes maintenance of appropriate body temperature (radiant warmer, incubator), adequate supply of fluids and electrolytes (excess fluids may worsen patent ductus arteriosus), glycemic control (normal: 2.6–8.0 mmol/L), maintenance of blood pressure (dopamine, dobutamine, or norepinephrine according to the appropriate blood pressure standard for preterm infants), and artificial nutrition (early start of parenteral nutrition, conversion to enteral nutrition as soon as possible). For treatment of patent ductus arteriosus (PDA), indomethacin, ibuprofen, acetaminophen, or surgical ligation is considered in hemodynamically significant PDA.


11. Prognosis

In the modern neonatal intensive care setting, death due to RDS itself has decreased greatly, but in extremely preterm infants, accompanying complications determine long-term prognosis.

Acute-phase complications

Air leak syndrome: Pneumothorax, pneumomediastinum, and pulmonary interstitial emphysema (PIE) are major complications of ventilator-associated lung injury. Their frequency has decreased with the spread of LISA/MIST and lung-protective ventilation strategies, but they can still occur before 28 weeks. Patent ductus arteriosus (PDA), when hemodynamically significant, causes increased pulmonary blood flow and worsened oxygenation. Pulmonary hemorrhage is a rare but fatal complication that occurs mainly when pulmonary blood flow increases after surfactant administration.

Long-term complications

Bronchopulmonary dysplasia (BPD) is the most important long-term complication of RDS, occurring in about 25–50% of extremely preterm infants born before 28 weeks. BPD may require continued respiratory support, diuretics, and bronchodilator treatment for months to years, and affects lung function beyond childhood. Intracranial hemorrhage (IVH) occurs due to periventricular vascular fragility and blood pressure fluctuations, and severe (grade III–IV) IVH is a risk factor for serious neurodevelopmental sequelae. Retinopathy of prematurity (ROP) occurs due to hyperoxia exposure and prematurity, and laser treatment or anti-VEGF injection is needed in progressive disease. Neurodevelopmental outcomes: extremely preterm infants are at risk of cerebral palsy, cognitive delay, language delay, and learning disabilities, and regular developmental follow-up is needed until 2 years of corrected age and school age.


12. Prevention

The key to RDS prevention is antenatal steroid administration and prevention of preterm birth.

Antenatal corticosteroids

For all pregnant women at risk of preterm birth before 34 weeks, betamethasone 12 mg intramuscularly × 2 doses (24 hours apart) or dexamethasone 6 mg × 4 doses (12 hours apart) is recommended. WHO and ACOG guidelines recommend it at 22–34 weeks, and conditionally at 34–36 weeks (late preterm) as well. If delivery is delayed by 7 days or more after administration, repeat dosing (rescue course) may be considered, but evidence for the long-term safety of repeat dosing is limited.

Suppression of preterm labor

Established tocolytics (atosiban, indomethacin, nifedipine) are used to delay preterm birth, securing enough time for antenatal steroids to take full effect. Magnesium sulfate is given for fetal neuroprotection when at risk of preterm birth before 32 weeks.

Management of diabetic mothers

Optimizing glycemic control before and during pregnancy prevents fetal hyperinsulinemia and promotes lung maturation. The HbA1c targets recommended are <6.5% in the first trimester and <7.0% during pregnancy.

Optimizing place and timing of delivery

For extremely preterm infants born before 28 weeks, delivery at a medical institution equipped with level 3 or higher neonatal intensive care facilities improves survival and prognosis. In utero transfer before delivery is more advantageous than neonatal transport after birth. Minimizing unnecessary cesarean section before labor reduces the risk of TTN and RDS.


13. References

  1. Sweet DG, Carnielli VP, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology. 2023;120(1):3-23. DOI: 10.1159/000528914. PMID: 36863329.
  2. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-1729. DOI: 10.1164/ajrccm.163.7.2011060. PMID: 11401896.
  3. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child. 1959;97(5):517-523. PMID: 13649082.
  4. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515-525. PMID: 4561295.
  5. Verder H, Robertson B, Greisen G, et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med. 1994;331(16):1051-1055. DOI: 10.1056/NEJM199410203311603. PMID: 7935629.
  6. Göpel W, Kribs A, Ziegler A, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet. 2011;378(9803):1627-1634. DOI: 10.1016/S0140-6736(11)60986-0. PMID: 22030330.
  7. Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2012;(3):CD000510. DOI: 10.1002/14651858.CD000510.pub2. PMID: 22419276.
  8. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med. 2010;61:105-119. DOI: 10.1146/annurev.med.60.041807.123500. PMID: 19824817.
  9. Isayama T, Iwami H, McDonald S, Beyene J. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants. JAMA. 2016;316(6):611-624. DOI: 10.1001/jama.2016.10708. PMID: 27532916.
  10. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454. DOI: 10.1002/14651858.CD004454.pub3. PMID: 28321847.